PITTSBURGH, March 05, 2018 -- Krystal Biotech, Inc. (NASDAQ:KRYS), a gene therapy company advancing “off-the-shelf,” treatments for dermatological diseases, today announced that Krish Krishnan, Chief Executive Officer, will present a corporate overview and business update at the ROTH Capital Markets Growth Conference, taking place March 11-13 at the Ritz Carlton hotel in Laguna Niguel, California.
30th Annual ROTH Conference
Date: Monday, March 12
Time: 10:30am Pacific Time
Location: Ritz Carlton Hotel, Salon 6
Webcast: http://wsw.com/webcast/roth32/krys/
About Krystal Biotech
Krystal Biotech, Inc. (NASDAQ:KRYS) is a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases. For more information, please visit http://www.krystalbio.com.
CONTACT
Ashley R. Robinson
LifeSci Advisors
[email protected]


Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Washington Post Publisher Will Lewis Steps Down After Layoffs
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Anta Sports Expands Global Footprint With Strategic Puma Stake
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 



